蛋白质MRI对比剂:实现精准分子影像的有效途径
本文综述了精准分子影像对理想对比剂的要求,介绍了作者研发的新型蛋白质靶向MRI对比剂(ProCAs)系列,从第一代ProCA1到第三代ProCA32,其r1和r2值在1.5 T场强下较临床批准对比剂高6至10倍,并可通过多靶向修饰实现对多种关键分子生物标志物的高亲和力结合,其中ProCA32.collagen已用于多种癌症早期肝转移及肝肺纤维化的在体早期检测。
要点
- 理想精准分子影像对比剂需兼顾金属结合亲和力与弛豫率,小分子螯合物对比剂常难以两全。
- ProCA32的r1和r2值在1.5 T下较临床批准对比剂高6至10倍,高场下弛豫率亦显著更高。
- ProCA32.collagen可在体早期检测多种癌症的肝转移及肝、肺早期纤维化。
核心结论
- 蛋白质靶向MRI对比剂ProCAs通过二级球层和关联时间贡献弛豫率,可实现高弛豫率、金属稳定性和分子生物标志物靶向能力,用于精准MRI。
研究设计与样本
- 本文为综述,介绍精准分子影像理想对比剂的标准,讨论当前对比剂第一壳层配位水分子的弛豫率,并总结作者在新型蛋白质靶向MRI对比剂(ProCAs)方面的设计策略与优化方法。
关键影像表现/征象
- 从第一代ProCA1到第三代ProCA32,在1.5 T磁场下获得双高r1和r2值,较临床批准对比剂高6至10倍。
- ProCA32在高场下弛豫率值亦显著更高,可在小动物成像中实现高分辨率。
- 对ProCA32进行多靶向部分工程化修饰后,对一系列与多种慢性病相关的关键分子生物标志物具有强结合亲和力和特异性。
- ProCA32保持弛豫性能、优异的金属结合与选择性、血清稳定性及抗金属转移能力。
- 先导产品ProCA32.collagen通过映射肿瘤环境及肝、肺早期纤维化,实现了多种癌症早期肝转移的首次早期检测。
诊断标准与关键数值
- 原文未报告敏感度、特异度、AUC、阈值或分级标准等诊断效能数值。
临床应用与阅片要点
- 原文未据此给出具体的临床阅片或报告推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Cancer and other acute and chronic diseases are results of perturbations of common molecular determinants in key biological and signaling processes. Imaging is critical for characterizing dynamic changes in tumors and metastases, the tumor microenvironment, tumor-stroma interactions, and drug targets, at multiscale levels. Magnetic resonance imaging (MRI) has emerged to be a primary imaging modality for both clinical and preclinical applications due to its advantages over other modalities, including sensitivity to soft tissues, nondepth limitations, and the use of nonionizing radiation. However, extending the application of MRI to achieve both qualitative and quantitative precise molecular imaging with the capability to quantify molecular biomarkers for early detection, staging, and monitoring therapeutic treatment requires the capacity to overcome several major challenges including the trade-off between metal-binding affinity and relaxivity, which is an issue frequently associated with small chelator contrast agents. In this review, we will introduce the criteria of ideal contrast agents for precision molecular imaging and discuss the relaxivity of current contrast agents with defined first shell coordination water molecules. We will then report our advances in creating a new class of protein-targeted MRI contrast agents (ProCAs) with contributions to relaxivity largely derived from the secondary sphere and correlation time. We will summarize our rationale, design strategy, and approaches to the development and optimization of our pioneering ProCAs with desired high relaxivity, metal stability, and molecular biomarker-targeting capability, for precision MRI. From first generation (ProCA1) to third generation (ProCA32), we have achieved dual high r1 and r2 values that are 6- to 10-fold higher than clinically approved contrast agents at magnetic fields of 1.5 T, and their relaxivity values at high field are also significantly higher, which enables high resolution during small animal imaging. Further engineering of multiple targeting moieties enables ProCA32 agents that have strong biomarker-binding affinity and specificity for an array of key molecular biomarkers associated with various chronic diseases, while maintaining relaxation and exceptional metal-binding and selectivity, serum stability, and resistance to transmetallation, which are critical in mitigating risks associated with metal toxicity. Our leading product ProCA32.collagen has enabled the first early detection of liver metastasis from multiple cancers at early stages by mapping the tumor environment and early stage of fibrosis from liver and lung in vivo, with strong translational potential to extend to precision MRI for preclinical and clinical applications for precision diagnosis and treatment.
引用
- Li D, Kirberger M, Qiao J, et al. Protein MRI Contrast Agents as an Effective Approach for Precision Molecular Imaging. Invest Radiol. 2024. PMID: 38180819. doi:10.1097/RLI.0000000000001057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。